BRAIN Biotech AG

XTRA:BNN Voorraadrapport

Marktkapitalisatie: €48.1m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BRAIN Biotech Beheer

Beheer criteriumcontroles 2/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Aryan Moelker

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO4.7yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn3yrs
Gemiddelde ambtstermijn bestuur4yrs

Recente managementupdates

Recent updates

Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce

Sep 24
Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce

BRAIN Biotech AG (ETR:BNN) Screens Well But There Might Be A Catch

Aug 06
BRAIN Biotech AG (ETR:BNN) Screens Well But There Might Be A Catch

Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?

Jun 29
Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?

BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate

Apr 19
BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate

BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable

Mar 28
BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable

Is BRAIN Biotech (ETR:BNN) A Risky Investment?

Feb 16
Is BRAIN Biotech (ETR:BNN) A Risky Investment?

Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt

Sep 13
Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt

Here's What B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shareholder Ownership Structure Looks Like

Mar 21
Here's What B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shareholder Ownership Structure Looks Like

Is B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Weighed On By Its Debt Load?

Feb 14
Is B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Weighed On By Its Debt Load?

When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven?

Jan 18
When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven?

How Much Did B.R.A.I.N. Biotechnology Research and Information Network's(ETR:BNN) Shareholders Earn From Share Price Movements Over The Last Three Years?

Dec 31
How Much Did B.R.A.I.N. Biotechnology Research and Information Network's(ETR:BNN) Shareholders Earn From Share Price Movements Over The Last Three Years?

Are Institutions Heavily Invested In B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shares?

Dec 10
Are Institutions Heavily Invested In B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shares?

Should You Investigate B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) At €7.30?

Nov 17
Should You Investigate B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) At €7.30?

Analyse CEO-vergoeding

Hoe is Aryan Moelker's beloning veranderd ten opzichte van BRAIN Biotech's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-€9m

Mar 31 2024n/an/a

-€8m

Dec 31 2023n/an/a

-€8m

Sep 30 2023n/an/a

-€8m

Jun 30 2023n/an/a

-€7m

Mar 31 2023n/an/a

-€7m

Dec 31 2022n/an/a

-€7m

Sep 30 2022n/an/a

-€7m

Jun 30 2022n/an/a

-€8m

Mar 31 2022n/an/a

-€8m

Dec 31 2021n/an/a

-€4m

Sep 30 2021€957k€420k

-€5m

Jun 30 2021n/an/a

-€6m

Mar 31 2021n/an/a

-€6m

Dec 31 2020n/an/a

-€11m

Sep 30 2020€885k€280k

-€10m

Compensatie versus markt: Insufficient data to establish whether Aryan's total compensation is reasonable compared to companies of similar size in the German market.

Compensatie versus inkomsten: Aryan's compensation has increased whilst the company is unprofitable.

CEO

Aryan Moelker

4.7yrs

Tenure

€957,000

Compensatie

Mr. Adriaan Moelker, also known as Aryan, serves as Director of SolasCure Limited. He has been Chairman of the Management Board and Chief Executive Officer of BRAIN Biotech AG (formerly known as B.R.A.I.N....

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Adriaan Moelker
Chairman of the Management Board & CEO4.7yrs€957.00kgeen gegevens
Ulrich Putsch
Co-Founderno datageen gegevensgeen gegevens
Michael Schneiders
CFO & Member of Management Board2yrsgeen gegevensgeen gegevens
Ute Dechert
Vice President of Human Resources & Processes4yrsgeen gegevensgeen gegevens
Jurgen Eck
Consultant4.8yrs€392.00kgeen gegevens
Martin Langer
MD & Executive VPno datageen gegevensgeen gegevens
Alexander Pelzer
VP and Head of Research & Development - Zwingenberg1.8yrsgeen gegevensgeen gegevens
Robbert Hoekstra
Head of Group Finance2yrsgeen gegevensgeen gegevens
Paul Scholz
Technical Lead of Genome Editing Developmentno datageen gegevensgeen gegevens

3.0yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: BNN's management team is considered experienced (3 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Wiltrud Treffenfeldt
Independent Member of Supervisory Board4yrs€28.00kgeen gegevens
Stephen Catling
Independent Member of Supervisory Board4yrs€31.00kgeen gegevens
Michael Majerus
Independent Chairman of the Supervisory Board5.6yrs€51.00kgeen gegevens
Anna Eichhorn
Vice Chairwoman of the Supervisory Board7.6yrs€53.00kgeen gegevens
Christine Uekert
Independent Supervisory Board Member1.6yrsgeen gegevensgeen gegevens
Florian Schnabel
Supervisory Board Member1.6yrsgeen gegevensgeen gegevens

4.0yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: BNN's board of directors are considered experienced (4 years average tenure).